博腾股份全资子公司通过欧盟QP审计

Core Viewpoint - Chongqing Boteng Pharmaceutical Technology Co., Ltd. (referred to as "Boteng Co., Ltd.") announced that its wholly-owned subsidiary, Chongqing Boteng Pharmaceutical Co., Ltd. (referred to as "Boteng Pharmaceutical"), has successfully passed the EU Qualified Person (QP) audit and received a compliance statement from the EU QP, indicating that its quality management system meets EU GMP standards [1] Group 1 - The audit was conducted based on EU GMP Guidelines EudraLex Volume 4, EU Clinical Trial Regulation (536/2014), and GMP for IMP guidelines, covering various aspects such as quality management, production management, facilities, material systems, and packaging and labeling systems at the Chongqing formulation production base [1] - The successful completion of the QP audit allows Boteng Pharmaceutical to provide customized R&D and production services that meet international standards for global clients [1] - The announcement disclosed that the passing of the EU QP audit will not have a significant impact on the current performance of Boteng Co., Ltd. [1]